Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3,639 Comments
1,861 Likes
1
Xsavier
Active Contributor
2 hours ago
Anyone else curious but confused?
👍 258
Reply
2
Marshella
Insight Reader
5 hours ago
Who else is here just trying to learn?
👍 210
Reply
3
Tamon
Power User
1 day ago
I know there are others thinking this.
👍 101
Reply
4
Azai
Elite Member
1 day ago
Anyone else watching without saying anything?
👍 211
Reply
5
Oceane
Senior Contributor
2 days ago
Who else is trying to figure this out step by step?
👍 121
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.